Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on October 24, 2017. The filing serves as a Regulation FD disclosure regarding a corporate presentation for Surface Pharmaceuticals, Inc., a subsidiary of the Company. The presentation is utilized by management at investor conferences and meetings to describe Surface and the Company.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation and does not contain a financial statement or earnings release.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing solely discloses the existence and use of the attached corporate presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Surface Pharmaceuticals, Inc. Corporate Presentation dated October 2017) for specific operational details.
- Confirm that the presentation is not legally considered "filed" information under the Exchange Act unless specifically referenced elsewhere.
- Note that the registrant is Imprimis Pharmaceuticals, Inc., not Harrow, Inc., despite the metadata request.